Skip to main content
Fig. 7 | Journal of Experimental & Clinical Cancer Research

Fig. 7

From: Argininosuccinate synthase 1 suppresses tumor progression through activation of PERK/eIF2α/ATF4/CHOP axis in hepatocellular carcinoma

Fig. 7

Decitabine improves efficacy of anti-HCC chemotherapeutic drugs by increasing ASS1 expression in HCC cells a The results of ASS1 promoter activity pilot screening. b ASS1 promoter activity in HEK293 cells treated with 10 μM decitabine for 12 hr or 24 hr by luciferase assay. c ASS1 and CHOP expression levels in Huh7 cells, SNU475, and SNU449 cells treated with decitabine indicated concentration. d Representative of cell viability in Huh7 cells with combination treatment of cisplatin and decitabine. e, f Cell survival rates of Huh7 and SNU449 cells after combination treatment with 0, 10, or 20 μM cisplatin and 10 μM decitabine by nuclei counting. g Expression of apoptosis related proteins; cleaved caspase 3 and PARP activation form expression levels in Huh7 and SNU475 cells after combination treatment with 0, 10, or 20 μM cisplatin and 10 μM decitabine. At least triplicate analysis in each set of experiment. *P < 0.05 compared control group

Back to article page